Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Merck
Medtronic
Boehringer Ingelheim
Johnson and Johnson

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,518,130

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,518,130
Title:Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.
Inventor(s): Moyo; Victor (Ringoes, NJ), Garcia; Gabriela (Roslindale, MA)
Assignee: Merrimack Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:14/518,900
Patent Claims:1. A method of treating a patient having a tumor that expresses ErbB3and is identified as a triple negative breast cancer, the method comprising administering to the patient an effective amount of an anti-ErbB3 antibody, or antigen-binding fragment thereof, comprising a V.sub.H CDR1 sequence of SEQ ID NO:3, a V.sub.H CDR2 sequence of SEQ ID NO:4 and a V.sub.H CDR3 sequence of SEQ ID NO:5, and a V.sub.L CDR1 sequence of SEQ ID NO:6, a V.sub.L CDR2 sequence of SEQ ID NO:7 and a V.sub.L CDR3 sequence of SEQ ID NO:8, that binds to all or a portion of residues 92-104 of SEQ ID NO:41.

2. The method of claim 1, wherein the anti-ErbB3 antibody binds to the same epitope as an antibody comprising a V.sub.H sequence as shown in SEQ ID NO:1 and a V.sub.Lsequence as shown in SEQ ID NO:2.

3. The method of claim 1, wherein administration of the effective amount of the anti-ErbB3 antibody suppresses growth of the triple negative breast cancer tumor.

4. The method of claim 1, wherein the triple negative breast cancer is histopathologically characterized as having a basal-like phenotype.

5. The method of claim 1, wherein the triple negative breast cancer is histopathologically characterized as having a phenotype other than basal-like.

6. The method of claim 1, which further comprises administering to the patient an effective amount of at least one additional anti-cancer agent.

7. The method of claim 6, wherein the at least one additional anti-cancer agent is selected from the group consisting of platinum-based chemotherapy drugs, taxanes, tyrosine kinase inhibitors, anti-EGFR antibodies, anti-ErbB2 antibodies, and combinations thereof.

8. The method of claim 7, wherein the at least one additional anti cancer agent is a taxane and the taxane is paclitaxel.

9. The method of claim 6, wherein the at least one additional anti-cancer agent comprises an EGFR inhibitor.

10. The method of claim 9, wherein the EGFR inhibitor comprises an anti-EGFR antibody.

11. The method of claim 10, wherein the anti-EGFR antibody is selected from the group consisting of cetuximab, matuzumab, panitumumab, nimotuzumab and mAb 806.

12. The method of claim 9, wherein the EGFR inhibitor is a small molecule inhibitor of EGFR signaling selected from the group consisting of gefitinib, lapatinib, canertinib, pelitinib, and erlotinib HCL.

13. The method of claim 6, wherein the at least one additional anti-cancer agent comprises a VEGF inhibitor.

14. The method of claim 13, wherein the VEGF inhibitor comprises bevacizumab.

15. The method of claim 1, wherein the triple negative breast cancer tumor is a tumor which scores negative for estrogen receptor (ER) and progesterone receptor and yields a test result of 0, 1+, or 2+ using a semi-quantitative immunohistochemical assay using a polyclonal anti-HER2 primary antibody.

16. The method of claim 15, wherein the tumor is FISH negative for HER2 gene amplification.

17. A method of treating a patient having a tumor that expresses ErbB3and is identified as a triple negative breast cancer which has a basal-like phenotype, the method comprising administering to the patient an effective amount of an anti-ErbB3 antibody, or antigen-binding fragment thereof, comprising a V.sub.H CDR1 sequence of SEQ ID NO:3, a V.sub.H CDR2 sequence of SEQ ID NO:4 and a V.sub.H CDR3 sequence of SEQ ID NO:5, and a V.sub.L CDR1 sequence of SEQ ID NO:6, a V.sub.L CDR2 sequence of SEQ ID NO:7 and a V.sub.L CDR3 sequence of SEQ ID NO:8 that binds to all or a portion of residues 92-104 of SEQ ID NO:41.

18. The method of claim 17, wherein the anti-ErbB3 antibody binds to the same epitope as an antibody comprising a V.sub.H sequence as shown in SEQ ID NO:1 and a V.sub.Lsequence as shown in SEQ ID NO:2.

19. The method of claim 17, wherein the administration of the effective amount of the anti-ErbB3 antibody suppresses growth of the breast cancer tumor.

20. The method of claim 17, which further comprises administering to the patient an effective amount of at least one additional anti-cancer agent.

21. The method of claim 20, wherein the at least one additional anti-cancer agent is a taxane.

22. The method of claim 21, wherein the taxane is paclitaxel.

Details for Patent 9,518,130

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2004-02-12 ⤷  Free Forever Trial 2030-03-11
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2007-03-28 ⤷  Free Forever Trial 2030-03-11
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Free Forever Trial 2030-03-11
Amgen, Inc. VECTIBIX panitumumab Injection 125147 2006-09-27 ⤷  Free Forever Trial 2030-03-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Mallinckrodt
Moodys
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.